Objective. To highlight the molecular findings and clinical response of a patient with rapidly progressing, focally anaplastic, oncocytic thyroid carcinoma (OTC) treated with erlotinib.
Case Summary. A 69-year-old woman with recurrent, focally anaplastic OTC was given a therapeutic trial of erlotinib, a small molecule inhibitor of epidermal growth factor receptor (EGFR). Formalin-fixed, paraffin-embedded portions of the tumor were analyzed for EGFR expression, and tumor genomic DNA was amplified by polymerase chain reaction (PCR) and subjected to EGFR mutation analysis.
Discussion. An early and dramatic response was achieved with erlotinib. The tumor was focally positive for EGFR by immunostaining and two point mutations were identified, one on exon 18 and one on exon 20 in the tyrosine kinase (TK) domain.
Conclusion. Erlotinib or other novel protein kinase pathway inhibitors should be evaluated further in patients with aggressive thyroid cancer variants, who may exhibit these and perhaps other tyrosine kinase mutations. J Oncol Pharm Practice (2009) 15: 111—117.
Pasieka JLAnaplastic thyroid cancer. Current Opinion in Oncology2003; 15(1): 78-83.
2.
Chiu AC, Oliveira AA, Schultz PN, Ordonez NG, Sherman SIPrognostic clinicopathologic features in oncocytic neoplasia. Thyroid1996; 6: S29.
3.
Carcangiu ML , Steeper T., Zampi G., Rosai J.Anaplastic thyroid cancer: A study of 70 cases . Am J Clin Pathol1985; 83(2): 135-58.
4.
McIver B. , Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB et al. Anaplastic thyroid cancer: a 50-year experience at a single institution. Surgery2001; 130(6): 1028-34.
5.
Nel CJ, van Heerden JA, Goellner JR, Gharib H., McConahey WM, Taylor WF et al. Anaplastic cancer of the thyroid: A clinicopathologic study of 82 cases. Mayo Clin Proc1985; 60(1): 51-8.
6.
Tan RK, Finley RK, Driscoll D., Bakamjian V., Hicks Jr WL, Shedd DPAnaplastic cancer of the thyroid: A 24-year experience. Head Neck1995; 17(1): 41-7.
7.
Venkatesh YS , Ordonez NG, Schultz PN, Hickey RC, Goepfert H., Samaan NAAnaplastic cancer of the thyroid: A clinicopathologic study of 121 cases. Cancer1990; 66(2): 321-30.
8.
Moore Jr JH, Bacharach B., Choi HYAnaplastic transformation of metastatic follicular cancer of the thyroid. J Surg Oncol1985; 29(4): 216-21.
9.
Nakamura T., Yana I., Kobayashi T., Shin E., Karakawa K., Fujita S. et al. p53 gene mutations associated with anaplastic transformation of human thyroid cancers. Jpn J Cancer Res1992; 83(12): 1293-8.
10.
Ito T., Seyama T., Mizuno T., Tsuyama N., Hayashi T., Hayashi Y. et al. Unique association of p53 mutations with undifferentiated but not with differentiated cancers of the thyroid gland. Cancer Res1992; 52(5): 1369-71.
11.
Ito T., Seyama T., Mizuno T., Tsuyama N., Hayashi Y., Dohi K. et al. Genetic alterations in thyroid tumor progression: Association with p53 gene mutations. Jpn J Cancer Res1993; 84(5): 526-31.
12.
Moretti F., Farsetti A., Soddu S., Misiti S., Crescenzi M., Filetti S. et al. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic cancer cells. Oncogene1997; 14(6): 729-40.
13.
Komoike Y., Tamaki Y., Sakita I., Tomita N., Ohue M., Sekimoto M. et al. Comparative genomic hybridization defines frequent loss on 16p in human anaplastic thyroid cancer. Int J Oncol1999; 14(6): 1157-62.
14.
Quiros RM, Ding HG, Gattuso P., Prinz RA, Xu X.Evidence that one subset of anaplastic thyroid cancers are derived from papillary cancers due to BRAF and p53 mutations. Cancer2005; 103(11): 2261-8.
15.
Arteaga C.Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol2003; 30 (3 Suppl 7): 3-14.
16.
Langer CJEmerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. Int J Radiat Oncol Biol Phys2004; 58(3): 991-1002.
17.
Pao W., Miller VAEpidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions . J Clin Oncol2005; 23: 2556-68.
18.
Lynch TJ, Bell DW, Sordella R., Gurubhagavatula S., Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med2004; 350(21): 2129-39.
19.
Trotti A., Colevas AD, Setser A., Rusch V., Jaques D., Budach V. et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol2003; 13(3): 176-81.
20.
Nobuhara Y. , Onoda N., Yamashita Y., Yamasaki M., Ogisawa K., Takashima T. et al. Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines . Br J Cancer2005 ; 92(6): 1110-6.
21.
NCBI Database. http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=10251977 (accessed 2 January 2009)
22.
Kimchi-Sarfaty C., Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV et al. A `silent' polymorphism in the MDR1 gene changes substrate specificity. Science2007; 315(5811): 525-8.
23.
Bernig T., Boersma BJ, Howe TM, Welch R., Yadavalli S., Staats B. et al. The mannose-binding lectin (MBL2) haplotype and breast cancer: An association study in African-American and Caucasian women. Carcinogenesis2007; 28: 828-36.
24.
DeLellis RA, LLoyd R, Heitz PU, eds. WHO classification of tumors, pathology and genetics-tumors of endocrine organs . Lyon: IARC Press, 2004.
25.
Volante M., Landolfi S., Chiusa L., Palestini N., Motta M., Codegone A. et al. Poorly differentiated cancers of the thyroid with trabecular, insular and solid patterns. A clinico-pathological study of 183 cases. Cancer2004; 100(5): 950-7.
26.
Volante M., Collini P., Nikiforov YE, Sakamoto A., Kakudo K., Katoh R. et al. Poorly differentiated thyroid cancer: the turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach . Am J Surg Pathol2007; 31(8): 1256-64.
